Endothelial cell protein C receptor (EPCR) enhances the generation of activated protein C by the thrombinthrombomodulin complex. A soluble form of EPCR (sEPCR) is present in plasma. Two polymorphisms in the EPCR gene (6936A/G and 4678G/C) have been reported to influence the risk of venous thromboembolism. We aimed to investigate the relation between EPCR gene polymorphisms (6936A/G and 4678C/G) and deep venous thrombosis (DVT) and their relations to sEPCR level. This study involved 90 patients with DVT and 90 age and sexmatched healthy controls. Plasma levels of sEPCR were measured in 45 cases of the primary DVT by ELISA. PCRrestriction fragment length polymorphism (RFLP) was used for detection of EPCR polymorphisms (6936A/G and 4678G/C). Regarding 6936A/G, our results demonstrated that mutant genotypes (AG, GG) were associated with an increased risk for DVT [P < 0.001, odds ratio (OR) 4.125, 95% confidence interval (95% CI) 2.198-7.740] as well as its mutant allele G (P < 0.001, OR 2.549, 95% CI 1.601-4.061). The mutant genotypes were associated with increased levels of sEPCR. Although in 4678G/C, our results demonstrated that the mutant genotype (CC) was considered as a protective factor against DVT (P U 0.014, OR 0.289, 95% CI 0.108-0.776) as well as its mutant allele C (P U 0.02, OR 0.600, 95% CI 0.388-0.927), but it had no effect on sEPCR level. Our data suggest that 6936A/G polymorphism is a risk factor for DVT and is associated with elevated plasma levels of sEPCR, while 4678G/C polymorphism plays a role in protection against DVT. Blood Coagul Fibrinolysis 27:259-265
Introduction
A successful balance between the coagulation and fibrinolytic pathways is mandatory for normal haemostasis to maintain the integrity of the blood vessels after vascular injury [1] . This balance needs complex interactions between plasma proteins, platelets, blood flow and the endothelium [2] .
Thrombophilia results when genetic or acquired changes that enhance the coagulation factors or cause defect in the fibrinolytic pathway lead to inappropriate clot formation [3] . The predominant clinical manifestation of thrombophilia is venous thromboembolism (VTE) [4] .
Deep vein thrombosis (DVT) is a common preventable cause of death in adults affecting as high as 0.1% persons per year worldwide. Reported rate of DVT among African pregnant women was 48 cases per 100 000 births per year [5] . This incidence even rises in the postpartum period [6] . Furthermore, 41-95% of the emboli causing pulmonary embolism are derived from DVT [7] .
The risk factors for DVT include both acquired and genetic factors. Acquired factors involve prolonged bed rest, surgery, pregnancy or puerperium, hormonal treatment, varicose veins, long air travel, acute inflammatory bowel disease, rheumatological diseases, nephrotic syndrome and malignancies [8] [9] [10] .
Genetic risk factors include mutations in factors involved in the coagulation-fibrinolytic system as those causing deficiencies of antithrombin, protein C (PC) and protein S, factor V Leiden, prothrombin 20210A and fibrinogen 10034T [11] .
EPCR can be considered as a key component of the PC pathway, as it can increase the activity of PC/APC via the thrombin-thrombomodulin complex by five to 20-fold, leading to markedly elevated anticoagulation activity. Several mutants of EPCR have been identified with differential expression levels and function [12] . Soluble EPCR (sEPCR) is a soluble form of EPCR that is constituted by metalloprotease cleavage and present in normal human plasma [13] .
There are two identified polymorphisms in the EPCR gene: 6936A/G (rs 867186) and 4678G/C (rs 9574). EPCR polymorphism 6936A/G (corresponding to 4600A/G) occurs within the region of EPCR encoded by exon 4, near the 4600 position. They are single-nucleotide polymorphisms (SNPs) representative of two of the four different haplotypes in the EPCR gene, haplotype 3 (H3) and haplotype 1 (H1), respectively [14] .
Patients and methods
The present study was conducted on 90 patients with DVT. Patients were diagnosed by Doppler ultrasonography and selected among cases referred to the Vascular Department at Kasr EL-Aini Teaching Hospital, Cairo University from January 2013 to February 2014. Cases were divided into two groups A and B; each group includes 45 cases. Group A was subjected to sEPCR evaluation, had exclusion criteria including haematological diseases, liver and kidney dysfunctions, infections, autoimmune diseases, tumours, diabetes mellitus and intake of contraceptives, thrombolytic treatment or oral anticoagulant treatment. The previous conditions were excluded because they can alter sEPCR level or may cause DVT [15] .
Group B was not evaluated for sEPCR levels; 15 cases in this group had the same previous exclusion criteria except taking oral anticoagulant treatment. The other 30 cases had secondary causes for DVT; 17 cases had DVT in pregnancy or puerperium and 13 cases were receiving contraceptive treatment.
The control group included 90 age and sex-matched healthy individuals selected among normal people coming for routine check-up and their investigations revealed normal with no personal or family history of DVT.
They were divided into two groups (A and B); each group includes 45 participants. Group A was subjected to sEPCR assay. Group B was not evaluated for sEPCR level, with 30 cases of them having a history of pregnancy and taking contraceptive treatment without complications.
Patients were subjected to routine investigations, including complete blood picture, coagulation profile [prothrombin time, concentration, international normalization ratio (INR) and activated partial thromboplastin time (aPTT)] and assay of PC, protein S, antithrombin III and lupus anticoagulant.
They were all subjected to Doppler ultrasonography to confirm the diagnosis of DVT and follow up the effect of the treatment.
Finally, PCR-RFLP for the two EPCR polymorphisms (6936A/G and 4678G/C) was done for cases and control groups.
Sample collection A total of 10 ml of peripheral blood was obtained from each individual. Five millilitres of blood was placed in EDTA tube for DNA extraction and 5 ml in sodium citrate (1/10 volume) tube from which plasma was isolated for sEPCR estimation.
Both EDTA and plasma samples were stored at À208C for later use.
Detection of endothelial cell protein C receptor polymorphisms by PCR-RFLP EPCR polymorphisms (6936A/G) and (4678G/C) were determined using PCR according to the protocol published by Sesin et al. [16] All reactions were performed in a total volume of 25 ml using 1 ml of each primer.
PCR was performed using DNA thermal cycler (PTC-100 programmable thermal controller; MJ Research, Watertown, Massachusetts, USA). The thermocycler was programmed for initial heat denaturation at 948C for 5 min; amplification included 40 cycles with the following programme: denaturation at 948C for 1 min, annealing at 608C for 1 min, extension at 728C for 1 min. Last cycle extension was prolonged to 5 min at 728C.
With regard to EPCR polymorphism 6936A/G, after amplification, the PCR product (290 bp) was digested with PstI (Thermoscientific, Runcorn, Cheshire, UK) restriction enzyme, provided by New Test Company (Cairo, Egypt).
For EPCR polymorphism 4678 G/C, after amplification, the PCR product (314 bp) was digested with DdeI (New England BioLabs, Hitchin, Hertfordshire, UK) restriction enzyme, provided by Lab Technology Company (Cairo, Egypt).
The digested products were detected by capillary electrophoresis using QIAxcel instrument and QIAxcel DNA High-resolution Kit provided by Clini Lab Company (Figs 1 and 2 ).
sEPCR levels were estimated using ELISA kit (WKEA, Med Supplies, China) provided by Leader Trade Company. Results of allele frequencies of the two EPCR polymorphisms are summarized in Table 2 .
Results of plasma soluble endothelial cell protein C receptor assay by ELISA sEPCR level was measured in group (A) patients and group (A) controls. In patients, sEPCR ranged from 110.0 to 2833.5 ng/l with a median value of 358.5, while in controls, sEPCR ranged from 74.0 to 1274.0 ng/l with a median value of 306.5, which was statistically insignificant (P ¼ 0.282). A highly significant relation was only detected between EPCR polymorphism (6936A/G) and sEPCR levels (Tables 3 and 4 
) (Figs 3 and 4).
No association was detected between EPCR genotype and presence of other risk factors of DVT (pregnancy, puerperium and contraceptives treatment) among the studied groups (Table 5) . 
Discussion
In the present study, we found higher frequencies of the mutant EPCR (6936A/G) genotypes (AG, GG) in DVT cases (73.3%) than the control group (40.0%); it showed higher risk to DVT by four-fold than the wild type (AA) (P < 0.001, OR 4.125, 95% CI 2.198-7.740). The homozygous mutant genotype (GG) showed increased risk of DVT by nine-fold compared with the wild type (AA). Also, the mutant allele (G) showed higher risk than the wild allele (A) (P < 0.001, OR 2.549, 95% CI 1.601-4.061).
That was in agreement with the result of studies by Saposnik et al. [18] and Yin et al. [19] .
On the contrary, Xu-dong et al. [7] and Medina et al. [20] found no significant difference in the frequency of the GG genotype between the cases and controls. That could be referred to low frequency of the GG genotype among their studied groups. These different results could be explained by the fact that genotypes show different distribution among different ethnic groups.
Due to the difficulty found in selecting patients with primary DVT and no secondary risk factors, we decided to include patients with common risk factors (pregnancy, puerperium and contraceptives treatment). Such factors are commonly found among normal populations. So, our study included 17 cases of DVT following pregnancy, puerperium or contraceptives treatment and 30 normal women with a history of previous multiple pregnancies or taking contraceptive pills without complications.
By comparing EPCR 6936A/G genotype in the study participants with and without these risk factors, there was no significant difference. So, the role of the G allele in pathogenesis of DVT is independent of these risk factors. But the reverse could be incorrect, that is EPCR genotype could increase the risk of thrombosis during pregnancy, puerperium or contraceptive treatment. It could augment the condition of increased resistance to APC that is normally observed in the second and third trimesters [21] . Women with inherited thrombophilia had shown an increased risk of thrombosis up to eight-fold [22] .
EPCR 6936A/G causes conformational changes in the protein due to serine to glycine substitution at residue 219 that is located in the transmembrane domain and became adjacent to another Gly at residue 218. The GlyGly interaction affects the stability of the helical structure of transmembrane domain such that the cleavage site is exposed. Increased shedding of membrane-attached EPCR occurs after cleavage by matrix metalloproteinases, leading to increased levels of sEPCR in the circulation and subsequently reduced APC because sEPCR inhibits both APC activity and PC activation by competing for PC with membrane-associated EPCR [23] .
EPCR genotype and risk of DVT confirmed Zoheir et al. 263 On the basis of the previous theory, we analysed sEPCR levels in relation to EPCR genotypes, and higher levels were associated with the mutant genotypes (AG and GG).
These results are inconsistent with the previous researches [7, 14, 20, 24] .
With regard to EPCR polymorphism 4678G/C, the homozygous mutant genotype (CC) showed lower risk than the homozygous wild type (GG), and this was statistically significant (P ¼ 0.014, OR 0.289, 95% CI 0.108-0.776), that is the homozygous mutant genotype (CC) decreased the risk to DVT by 0.289 compared with the wild type (GG). Analysis of sEPCR in relation to EPCR polymorphism 4678G/C genotypes in DVT patients revealed no significant association.
Again, these results were not affected by previously mentioned risk factors.
In agreement to our result, Karabıyık et al. [24] reported that 4678G/C may have protective effects against VTE (P ¼ 0.0175, OR 0.82, 95% CI 0.31-2.20). Also, Medina et al. [20] reported that the carriers of the CC genotype had a reduced risk of VTE (OR 0.59, 95% CI 0.41-0.84).
Finally, Medina et al. [25] confirmed that individuals carrying EPCR polymorphism 4678G/C have reduced VTE risk, increased plasma activated PC levels and reduced plasma sEPCR levels and those with homozygous mutant EPCR (6936A/G) genotype have an increased VTE risk and increased plasma sEPCR levels.
No significance relation was found between EPCR genotype and age, sex or family history.
The mechanism explaining the protective role of 4678C allele against venous thrombosis remains to be identified. Increased level of APC has been reported in association with 4678C allele. However, it has to be investigated whether it causes a rise in APC levels by itself or it is linked to other genetic variations affecting coagulation or fibrinolytic system [18] .
In conclusion, our data suggest that 6936A/G polymorphism is a risk factor for DVT and is associated with elevated plasma levels of sEPCR, while 4678G/C polymorphism plays a role in protection against DVT and had no effect on sEPCR level. Larger scale studies are recommended to support our results.
Despite some limitations, mainly lack of financial supports that limit the number of our studied groups, this study still contributes to the understanding of the role of EPCR polymorphisms in the development of DVT and provides insight to their frequencies in Egypt. 
